From Gut to Metabolism: Exploring the Intersection of Inflammatory Bowel Disease and Systemic Metabolic Dysfunction - PubMed
12 hours ago
- #metabolic syndrome
- #inflammatory bowel disease
- #systemic inflammation
- Inflammatory Bowel Disease (IBD) includes Crohn's disease and ulcerative colitis, recognized as systemic conditions with extraintestinal manifestations.
- IBD prevalence has risen alongside obesity and metabolic disorders like type 2 diabetes, cardiovascular disease, and liver disease, suggesting shared biological pathways.
- Mechanisms linking IBD and metabolic dysfunction include systemic meta-inflammation, gut barrier dysfunction, and altered lipid and glucose metabolism.
- Obesity and insulin resistance impact IBD outcomes by altering drug pharmacokinetics and increasing treatment failure and infection risks.
- Metabolic-directed therapies, such as GLP-1 receptor agonists, may offer dual benefits for metabolic control and inflammation, though evidence is mostly observational.
- The review highlights the need for metabolic screening in IBD care and further research to address gut inflammation and systemic metabolic disease.